-

Ollin Biosciences to Participate in Two Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.

Piper Sandler Biopharma Symposium

1x1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA

UBS Private Biotech Summit

1x1 Meetings: Monday, May 18, 2026
Location: New York, NY

About Ollin Biosciences

Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

Contacts

Media & Investors:
Katie Engleman
1AB
katie@1abmedia.com

Industry:

Ollin Biosciences, Inc.

Release Versions
English

Contacts

Media & Investors:
Katie Engleman
1AB
katie@1abmedia.com

Social Media Profiles
Ollin Biosciences LinkedIn
Ollin Biosciences X
More News From Ollin Biosciences, Inc.

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Ann...

Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds and other institutional investors new to Ollin, including a16z Bio...

Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at Clinical Trials at the Summit 2026

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from Jun...
Back to Newsroom